Henlius Biotech’s HLX11 Meets Phase 3 Trial Goals

Shanghai Henlius Biotech, Inc. Class H (HK:2696) has released an update.

Shanghai Henlius Biotech, Inc. has announced that its phase 3 clinical trial for HLX11, a biosimilar to pertuzumab for HER2-positive, HR-negative breast cancer, has successfully met its primary endpoint. The study, which is critical for the development of new neoadjuvant therapies, compared the efficacy and safety of HLX11 against the reference drug Perjeta. This development could have significant market implications, considering the multi-billion dollar global sales value of pertuzumab injections.

For further insights into HK:2696 stock, check out TipRanks’ Stock Analysis page.